<code id='85620FCE50'></code><style id='85620FCE50'></style>
    • <acronym id='85620FCE50'></acronym>
      <center id='85620FCE50'><center id='85620FCE50'><tfoot id='85620FCE50'></tfoot></center><abbr id='85620FCE50'><dir id='85620FCE50'><tfoot id='85620FCE50'></tfoot><noframes id='85620FCE50'>

    • <optgroup id='85620FCE50'><strike id='85620FCE50'><sup id='85620FCE50'></sup></strike><code id='85620FCE50'></code></optgroup>
        1. <b id='85620FCE50'><label id='85620FCE50'><select id='85620FCE50'><dt id='85620FCE50'><span id='85620FCE50'></span></dt></select></label></b><u id='85620FCE50'></u>
          <i id='85620FCE50'><strike id='85620FCE50'><tt id='85620FCE50'><pre id='85620FCE50'></pre></tt></strike></i>

          entertainment

          entertainment

          author:explore    Page View:669
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic
          Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

          AdobeTheFoodandDrugAdministrationhasclearedOtsukaPharmaceutical’sdigitaltreatmentformajordepressived

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

          4:01FormerPresidentDonaldTrumpwavesashestepsoffhisplaneatRonaldReaganWashingtonNationalAirport,Aug.3